NY-ESO-1 peptide vaccine
- Generic Name
- NY-ESO-1 peptide vaccine
- Drug Type
- Biotech
- Background
NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Ovarian Cancer Stage IVOvarian Cancer Stage 3Ovarian Cancer Stage III
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 24
- Registration Number
- NCT05479045
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath